One of the most difficult aspects of regenerative medicine is understanding and making good decisions regarding the source of stem cells used for treatment.
What products are derived from those tissues? What do those products contain? What don’t those products contain?
Amniotic Allograft Tissue is a minimally manipulated tissue derived from umbilical cord tissue for use in humans. It is intended to supplement and replace damaged or inadequate connective tissue and cells. The injection contains a variety of growth factors, cytokines, hyalauronic acid and mesenchymal stem cells. The Mesenchymal Stem Cells from Umbilical Cord tissue have a much higher rate of proliferation when compared to mesenchymal stem cells derived from either adipose (fat) or bone marrow.
1. The use of the umbilical product is less invasive when compared bone marrow aspiration, or
adipose tissue extraction. This results in less pain for the patient and a much shorter procedure
2. Umbilical cord and Placental tissue products does not use any material obtained directly from the embryo or fetus.
3. Because umbilical cord Mesenchymal Stem Cell's lack MHC-II and are therefore hypo-immunogenic, they are
inherently unlikely to result in an allergic reaction for the recipient.
4. Umbilical Stem Cells's have a strong anti-inflammatory effect, reducing the expression of
inflammatory cytokines. This anti-inflammatory effect is maintained as they multiply.
5. Amniotic Allograft stem cell product is processed from donated human tissue from full term, c-section deliveries in accordance with the FDA and the American Association of Tissue Banks (AATB) standards.
Placental tissue allograft is regulated as a human cell, tissue, or cellular or tissue-based product (HCT/P) under 21 CFR Part 1271 and Section 361 of the Public Health Service Act.
1. Sabapathy V, Sundaram B, VM S, Mankuzhy P, Kumar S (2014) Human Wharton’s Jelly Mesenchymal Stem Cells Plasticity Augments Scar-Free Skin Wound Healing with Hair Growth. PLoS ONE 9(4): e93726. doi:10.1371/journal.pone.0093726
2. F Gao et.al. Mesenchymal stem cells and immunomodulation: current status and future prospects Cell Death and Disease (2016) 7, e2062; doi:10.1038/cddis.2015.327.